CCNE1 and osteosarcoma: As the presence of a subtype of LMW-cyclin E1 in osteosarcoma was shown at 33–47 kDa in Western blot assay (Figure 1D), we analyzed the expression level of LMW-cyclin E1 in relation to patient prognosis, and the results showed that the expression of LMW-cyclin E1 was significantly correlated with the overall survival and progression-free survival of osteosarcoma patients (Figure 2D).